These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27035498)

  • 21. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
    Maselli DJ; Singh H; Diaz J; Peters JI
    Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timing is everything: Targeting IgE to reduce asthma exacerbation risk.
    O'Byrne PM; Tworek D
    J Allergy Clin Immunol; 2015 Dec; 136(6):1486-1487. PubMed ID: 26654197
    [No Abstract]   [Full Text] [Related]  

  • 23. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
    Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
    Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
    Kupryś-Lipińska I; Molińska K; Kuna P
    Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies.
    Palomares Ó; Sánchez-Ramón S; Dávila I; Prieto L; Pérez de Llano L; Lleonart M; Domingo C; Nieto A
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between pretreatment specific IgE and the response to omalizumab therapy.
    Wahn U; Martin C; Freeman P; Blogg M; Jimenez P
    Allergy; 2009 Dec; 64(12):1780-7. PubMed ID: 19627273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of socioeconomic risk factors and mental health on asthma.
    Le TP; Sutherlin TK; Teverbaugh LA; Gleason MM; Carlson JC
    Ann Allergy Asthma Immunol; 2021 May; 126(5):453-457. PubMed ID: 33610758
    [No Abstract]   [Full Text] [Related]  

  • 29. [A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens].
    Sugino Y; Sanda R; Takagi Y; Kato M; Ohta A; Okumura J; Nagai H
    Arerugi; 2010 Nov; 59(11):1572-9. PubMed ID: 21119303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome?
    Cazzola M; Mura M; Segreti A; Mattei MA; Rogliani P
    Allergy; 2009 Sep; 64(9):1389-90. PubMed ID: 19392997
    [No Abstract]   [Full Text] [Related]  

  • 31. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
    Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
    J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab effectively protects against early and late allergic responses in asthma after 4 weeks.
    Trischler J; Lieb A; Arnold M; Schulze J; Rosewich M; Schubert R; Bottoli I; Zielen S
    Allergy; 2017 Dec; 72(12):1912-1915. PubMed ID: 28581121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of anti-IgE therapy beyond allergic asthma.
    Stokes JR; Casale TB
    J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omalizumab for asthma.
    Strunk RC; Bloomberg GR
    N Engl J Med; 2006 Jun; 354(25):2689-95. PubMed ID: 16790701
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of omalizumab treatment in a man with occupational asthma and eosinophilic granulomatosis with polyangioitis.
    Caruso C; Gencarelli G; Gaeta F; Valluzzi RL; Rumi G; Romano A
    Ann Allergy Asthma Immunol; 2018 Feb; 120(2):209-211. PubMed ID: 29290513
    [No Abstract]   [Full Text] [Related]  

  • 37. Monitoring Allergic Patients on Omalizumab with Free and Total Serum IgE Measurements.
    Hamilton RG
    J Allergy Clin Immunol Pract; 2016; 4(2):366-8. PubMed ID: 26968963
    [No Abstract]   [Full Text] [Related]  

  • 38. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
    Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab.
    MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2017 May; 139(5):1680-1682.e10. PubMed ID: 28259446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.